Enlibrium gets $15M to use metformin analogs for cancer
Enlibrium's technology, licensed out of UCLA, will use diabetes drug metformin to shut down energy production in cancer cells - providing a potentially new frontline treatment for the disease.
Enlibrium's technology, licensed out of UCLA, will use diabetes drug metformin to shut down energy production in cancer cells - providing a potentially new frontline treatment for the disease.
A next-gen form of ubiquitous diabetes drug metformin could have some serious impact on the type 2 diabetes market - as evidenced in some promising Phase 2 data from San Diego startup Elcelyx.
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
Diabetes drug metformin may be as effective as it’s ubiquitous, but it’s known to throws the stomach’s balance out of whack. Half the patients experience diarrhea and a quarter vomiting, so patients often scale back on metformin – or stop using it entirely. Also, microbiome imbalances are consistently being linked now to obesity. Colorado startup MicroBiome Therapeutics is […]